Longitudinal analysis of patient-reported symptoms post-autologous stem cell transplant and their relationship to inflammation in patients with multiple myeloma

References

• Attal M, Lauwers-Cances V, Marit G, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med 2012;366:1782–1791.
   PubMed Web of Science ®Google Scholar
• McCarthy PL, Owzar K, Hofmeister CC, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med 2012;366:1770–1781.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Freeman J, Weiss L, et al. The clinical safety of lenalidomide in multiple myeloma and myelodysplastic syndromes. Expert Opin Drug Saf 2012;11:107–120.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Weller E, Jagannath S, et al. Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma. J Clin Oncol 2009;27:5713–5719.
   PubMed Web of Science ®Google Scholar
• Venon MD, Roccaro AM, Gay J, et al. Front line treatment of elderly multiple myeloma in the era of novel agents. Biologics 2009;3:99–109.
   PubMedGoogle Scholar
• Wang XS, Shi Q, Shah N, et al. Inflammatory markers and development of symptom burden in patients with multiple myeloma during autologous stem cell transplantation. Clin Cancer Res 2014;20:1366–1374.
   PubMed Web of Science ®Google Scholar
• Jones D, Vichaya EG, Wang XS, et al. Validation of the M. D. Anderson Symptom Inventory multiple myeloma module. J Hematol Oncol 2013;6:13.
   Google Scholar
• Kast RE. Evidence of a mechanism by which etanercept increased TNF-alpha in multiple myeloma: new insights into the biology of TNF-alpha giving new treatment opportunities–the role of bupropion. Leuk Res 2005;29:1459–1463.
   PubMed Web of Science ®Google Scholar
• Seshasayee D, Valdez P, Yan M, et al. Loss of TACI causes fatal lymphoproliferation and autoimmunity, establishing TACI as an inhibitory BLyS receptor. Immunity 2003;18:279–288.
   PubMed Web of Science ®Google Scholar
• Jurisic V, Colovic M. Correlation of sera TNF-alpha with percentage of bone marrow plasma cells, LDH, beta2-microglobulin, and clinical stage in multiple myeloma. Med Oncol 2002;19:133–139.
   PubMed Web of Science ®Google Scholar
• Charlson M, Szatrowski TP, Peterson J, et al. Validation of a combined comorbidity index. J Clin Epidemiol 1994;47:1245–1251.
   PubMed Web of Science ®Google Scholar
• Cleeland CS, Mendoza TR, Wang XS, et al. Assessing symptom distress in cancer patients: the M.D. Anderson Symptom Inventory. Cancer 2000;89:1634–1646.
   Google Scholar
• Wang XS, Williams LA, Krishnan S, et al. Serum sTNF-R1, IL-6, and the development of fatigue in patients with gastrointestinal cancer undergoing chemoradiation therapy. Brain Behav Immun 2012;26: 699–705.
   Google Scholar
• Wang XS, Shi Q, Williams LA, et al. Serum interleukin-6 predicts the development of multiple symptoms at nadir of allogeneic hematopoietic stem cell transplantation. Cancer 2008;113:2102–2109.
   PubMed Web of Science ®Google Scholar
• Wang XS, Shi Q, Williams LA, et al. Inflammatory cytokines are associated with the development of symptom burden in patients with NSCLC undergoing concurrent chemoradiation therapy. Brain Behav Immun 2010;24:968–974.
   PubMed Web of Science ®Google Scholar
• Reuben JM, Lee BN, Li C, et al. Biologic and immunomodulatory events after CTLA-4 blockade with ticilimumab in patients with advanced malignant melanoma. Cancer 2006;106:2437–2444.
   PubMed Web of Science ®Google Scholar
• Nagin D. Group-based modeling of development. Cambridge, MA: Harvard University Press; 2005.
   Google Scholar
• Shi Q, Mendoza TR, Gunn GB, et al. Using group-based trajectory modeling to examine heterogeneity of symptom burden in patients with head and neck cancer undergoing aggressive non-surgical therapy. Qual Life Res 2013;22:2331–2339.
   PubMed Web of Science ®Google Scholar
• Wang XS, Zhao F, Fisch MJ, et al. Prevalence and characteristics of moderate to severe fatigue: a multicenter study in cancer patients and survivors. Cancer 2014;120:425–432.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Delforge M, Beksac M, et al. Management of treatment-emergent peripheral neuropathy in multiple myeloma. Leukemia 2012;26:595–608.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Chen C, Spencer A, et al. Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia 2009;23:2147–2152.
   PubMed Web of Science ®Google Scholar
• Schneider P, Mackay F, Steiner V, et al. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med 1999;189:1747–1756.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Schlossman RL, Weller E, et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002;100:3063–3067.
   PubMed Web of Science ®Google Scholar
• Wierzbowska A, Urbanska-Rys H, Robak T. Circulating IL-6-type cytokines and sIL-6R in patients with multiple myeloma. Br J Haematol 1999;105:412–419.
   PubMed Web of Science ®Google Scholar
• Prince HM, Schenkel B, Mileshkin L. An analysis of clinical trials assessing the efficacy and safety of single-agent thalidomide in patients with relapsed or refractory multiple myeloma. Leuk Lymphoma 2007; 48:46–55.
   PubMed Web of Science ®Google Scholar
• Genovese MC, Kremer JM. Treatment of rheumatoid arthritis with etanercept. Rheum Dis Clin North Am 2004;30:311–vii.
   PubMed Web of Science ®Google Scholar
• Ma Y, Yamazaki T, Yang H, et al. Tumor necrosis factor is dispensable for the success of immunogenic anticancer chemotherapy. Oncoimmunology 2013;2:e24786.
   PubMed Web of Science ®Google Scholar
• Mohty M, Brissot E, Savani BN, et al. Effects of bortezomib on the immune system: a focus on immune regulation. Biol Blood Marrow Transplant 2013;19:1416–1420.
   PubMed Web of Science ®Google Scholar